
Germ-specific diagnosis is hard
but necessary
Inappropriate treatment does not prevent hospitalization (40%, of >65 with pneumonia end up hospitalized), and antibiotic misuse leads to antimicrobial resistance





02
Doctors can diagnose pneumonia, but cannot easily identify the underlying microorganism
03
By guidelines, they must prescribe broad-spectrum antibiotics to every patient, despite 50% are actually viral
04
Inappropriate treatment does not prevent the patient from ending up hospitalized (cost > $30k /patient)
01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide
05
Antibiotic overuse leads to antimicrobial resistance (AMR), #1 world cause of death by 2050
Our Team
Jordan Parker

Position / Role
Max Johnson

Position / Role
Drew Carlyle

Position / Role
Morgan James

Position / Role

About

We are developing a quantitative analysis capable of detecting all microrganisms in both clinical and non-clinical samples, using a fast and cheap technology which can be deployed at the point of care.

Meet the Founders

Giulio Deangeli
MD, PhDc, MBiotech, MMedSci, BEng
Forbes 30 under 30, North America
Final year PhD candidate in AI, Cambridge
5 degrees in parallel, summa cum laude
Harvard HIP Scholarship, ranked in top 5%
World Vice-Champion Neuroscience, IBB
2 books, papers in Science, Cell, Brain

Cristiano Peron
MD, PhD
PhD in translational medicine, Oxford
Clinical Fellow Oxford University Hospital
Fellow, Robert Langer’s family office
Medical Doctor, summa cum laude
Armenise-Harvard Fellowship, Harvard
Papers in Cell and other journals

Fidelius von Rehlingen-Prinz
MD, PhD, MBAc
Advisory board, Kaliber Labs Inc., San Francisco
Medical advisor, Longevital, Munich
CFO, Sustain Surgical Inc., New York
PhD in receptor-specific therapies, Nuremberg
Medical Doctor, summa cum laude
Papers in leading clinical journals


How it works

Competitor approaches



Device intrinsic value < $8,000, consumables
< $20-30 /test
Germ-specific diagnosis is hard
but necessary
Inappropriate treatment does not prevent hospitalization (40%, of >65 with pneumonia end up hospitalized), and antibiotic misuse leads to antimicrobial resistance
Antibiotic overuse leads to antimicrobial resistance (AMR), #1 world cause of death by 2050

05

04
Inappropriate treatment does not prevent the patient from ending up hospitalized (cost > $30k /patient)
03
By guidelines, they must prescribe broad-spectrum antibiotics to every patient, despite 50% are actually viral

Doctors can diagnose
pneumonia, but cannot
easily identify the underlying
microorganism
02


01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide
01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide




02
Doctors can diagnose
pneumonia, but cannot
easily identify the underlying
microorganism
03
By guidelines, they must prescribe broad-spectrum antibiotics to every patient, despite 50% are actually viral
04
Inappropriate treatment does not prevent the patient from ending up hospitalized (cost > $30k /patient)
01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide
05
Antibiotic overuse leads to antimicrobial resistance (AMR), #1 world cause of death by 2050

Any sample works
Compatible with respiratory swab, blood, urine, saliva, stool…
Point of care
Can sit on a desk, no lab required
Fast
Result in 10-15 minutes
Cheap
Device intrinsic value
< $10,000, consumables
< $50 /test
Quantitative
Customizable panel of 50+ viruses, bacteria, and fungi in 1 test
Point of care
Can sit on a desk, no lab required
Fast
Result in 10-15 minutes
Cheap
Device intrinsic value
< $10,000, consumables
< $50 /test
Quantitative
Customizable panel of 50+ viruses, bacteria, and fungi in 1 test

One test to rule them all

Giulio Deangeli

↗
2024 - Final year PhD candidate, University of Cambridge
2021 - «100 number ones» by Forbes
2020 - 5 university courses in parallel, 30/30 GPA
2018 - Harvard HIP Scholarship, ranked in top 5%
2016 - Amgen Scholarship, Cambridge, ranked #1
2013 - World Vice-Champion Neuroscience, IBB
Author of 2 books; papers in Science, Cell and Brain
MD, PhDc, MBiotech, MMedSci, BEng
Cristiano Peron

↗
2023 - PhD, University of Oxford
2023 - Clinical Fellow Oxford University Hospital
2021 - Old Silver VC Fellow, Boston
2019 - Medical Doctor, summa cum laude
2018 - Armenise-Harvard Fellowship, Harvard University
2017 - IEF Fellowship, Columbia university
Author of papers in Cell and other peer reviewed journals
MD, PhD